|Dr. Emil D. Kakkis M.D., Ph.D.||Founder, Pres, CEO & Director||1.37M||N/A||1960|
|Mr. John Richard Pinion II||Chief Quality Operations Officer & Exec. VP of Translational Sciences||806.19k||N/A||1966|
|Mr. Erik Harris||Exec. VP & Chief Commercial Officer||848.24k||N/A||1971|
|Mr. Theodore A. Huizenga||Sr. VP, Corp. Controller & Principal Accounting Officer||N/A||N/A||1971|
|Mr. Dennis Karl Huang||Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP||N/A||N/A||1965|
|Ms. Danielle Keatley||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Karah Herdman Parschauer J.D.||Chief Legal Officer & Exec. VP||N/A||N/A||1978|
|Mr. Ernie W. Meyer||Chief HR Officer & Exec. VP||N/A||N/A||1964|
|Mr. Thomas R. Kassberg||Chief Bus. Officer & Exec. VP||N/A||N/A||1960|
|Mr. Vimal Srivastava||Sr. VP of Bus. Devel. & Alliance Management||N/A||N/A||1965|
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc.’s ISS governance QualityScore as of 1 September 2023 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 7; Compensation: 5.